Internal Medicine&nbsp;&nbsp;&nbsp;

What is your treatment approach for hidradenitis suppurativa?

Do you reserve biologics for more systemic involvement? When do you initiate biologics such as secukinumab?

How do you determine if a pyoderma gangrenosum lesion is “burned out"?

What changes do you make to your treatment approach to adapt to this altered disease state?

How would you treat disseminated flat warts in an immunosuppressed patient with skin of color?

How do you balance concern for causing skin hypopigmentation with many of the traditional treatment modalities we have?

What treatment approach is best for management of neutrophilic dermatosis in a patient with acute myeloid leukemia? Any suggestions for long term management?

After corticosteroids, what second line agent do you select to treat drug induced hypersensitivity syndrome (also known as DRESS syndrome)?

How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?

Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?

How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?

SLE manifestations include arthralgias and cytopenias which are stable. Previously did well on methotrexate, but developed GI side effects. HCQ is on ...

What have you found to be effective for keratosis pilaris?

Would you recommend continuing Accutane in a teenage female who has experienced a drop in calcium to 8.8 and reductions in albumin and protein levels one month into therapy?

Given that Accutane can affect calcium homeostasis, would you recommend continuing Accutane or are additional steps or workup warranted?

What are the benefits and potential risks of using bisphosphonates for pseudoxanthoma elasticum?

How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?

Would you view this as a sign that disease is not adequately controlled despite labs and imaging suggesting no active vasculitis?

When would you pursue genetic testing for severe recalcitrant atopic dermatitis?

What treatments have you found most effective in removing syringomas?

What specific settings and devices do you prefer to use?

What treatment modalities have you had success with for treating recalcitrant warts?

How do you approach Pityriasis rubra pilaris that is retinoid resistant?

Do you have a preference for biologics or phosphodiesterase inhibitors?

Are you comfortable utilizing Stelara (ustekinumab) as biologic treatment of psoriasis for patients with a history of severe latex allergy?

What role does oral roflumilast play in dermatology?

Does the presence of psoriatic arthritis affect your decision to use an anti-IL-17 or IL-23 drug in your psoriasis patients?

How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?

The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.

How do you manage polymorphic light eruption (PMLE)?

How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?

Would you be comfortable combining a TNFi with Rituxan in this patient?

What is your approach to deciding when to stop therapy for cutaneous Mycobacterium chelonae infections?

What is your approach for severe SCLE in patients unable to tolerate HCQ?

Do you utilize AIT for atopic dermatitis if there is no AR present?

What therapies do you recommend for patients with recalcitrant seborrheic dermatitis?

What treatment regimen have you found most effective? Do you recommend any lifestyle changes or prescribe oral azoles? Any experience with topical r...

How do you reassure families that no allergy testing is needed for urticaria?

What work up do you pursue for splinter hemorrhages in an otherwise healthy patient?

What is your approach in counseling a patient with delusions of parasitosis?

How do you approach treating patients who develop psoriasis while on Dupixent?

Do you start/trial them on another biologic or just rely on topical therapies?

How have you incorporated biologics targeting the IL-36 pathway (e.g. Spevigo) into your treatment algorithm for psoriasis?

How do you approach managing nausea and GI side effects when initiating methotrexate?

What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?

How would you approach management of a young male patient with discoid lupus who has had minimal response to hydroxychloroquine (and subtherapeutic whole blood levels) who continues to use tobacco products?

What is your experience managing patients with chronic spontaneous urticaria occurring only at night?

Female in her early 40s with chronic spontaneous urticaria occurring consistently only at night for the past 4 years. Lesions develop only at night wh...

What is your stepwise approach to a patient with erosive gingivitis?

What treatment do you initiate before you have a clear diagnosis?

In difficult cases, what is your approach to find a causative agent of fixed drug or fixed food eruption?

Drug elimination is often helpful, but some triggers are not easy to identify because they are found in food items.

Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?

What is your approach to management of radiation-induced bullous pemphigoid?

How do you approach managing perioperative anxiety in Mohs patients?

What is your approach to managing pyoderma gangrenosum recalcitrant to oral steroids?

When do you switch to steroid-sparing medications? What steroid-sparing therapies do you prefer?

7 Answers available

Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?

Is there a role for empiric scabies treatment in itchy patients without clear clinical signs of scabies?

Do you empirically treat itchy patients -with a non specific rash- for scabies without obvious clinical findings for scabies?

How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?

What topical therapies have you found most effective for managing scalp psoriasis?

Do you use combination therapies such as betamethasone and calcipotriene foam?

Do you wait on initiating biologic therapy for guttate psoriasis?

If so, how long?

What biologic for psoriasis do you prescribe most often in patients with a history of malignancy?

How do you dose oral tranexamic acid for melasma?

Given the side effect profile and risk of relapse off oral TXA therapy, do you prefer pulse dosing (i.e. 3 months on, 3 months off) or continuous ther...

How do you approach work up for underlying rheumatologic disease in patients referred for chronic urticaria?

How do you approach treatment change in patients with psoriasis who have been stable on an IL-17 or IL-23 agent but then begin to have breakthrough skin disease?

Do you first try adding topicals or UV? At what point do you decide to switch biologics and at that point do you try to class switch to a different MO...

How are you utilizing vibratory devices for reducing pain associated with injection or procedures?

In which situations or patient populations do you find this useful? How is it sterilized?

What treatments do you consider for cholinergic urticaria refractory to high dose H1 blockers and omalizumab?

How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?

What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?

How have you incorporated new psoriasis therapies such as deucravacitinib and bimekizumab into your hierarchy of psoriasis treatments?

Are there patients that you find respond best to these therapies?

Do you discontinue IL-17A, IL-17A/F, or IL-23 blockade in pregnant patients with psoriasis?

How does the location or type of psoriasis affect your initial biologic choice?

Is narrow-band ultraviolet B (nbUVB) phototherapy contraindicated or recommended with caution in patients with a personal history of melanoma?

How would you treat pemphigus foliaceous in an elderly patient intolerant to oral steroids?

What are the best biologics for a pediatric patient with extensive guttate psoriasis that is poorly controlled on topicals?

Mother's insurance plan has a high deductible and phototherapy is inconvenient (family lives 50 minutes away).

What are some practical tips for caring for resource-limited patients with severe, Hurley Stage III hidradenitis suppurativa?

For instance - any tips regarding coordination of care/transportation, associated lymphedema management, wound care, and pain control would be welcome...

For how long would you treat Klebsiella aerogenes folliculitis of the face manifesting as a cystic lesion?

Would you combine antibiotics with isotretinoin?

How frequently do you recommend skin cancer screens in your patients with kidney transplants who are on immunosuppression?

Is there a subset of ANCA vasculitis patients for which you would try plasma exchange?

How do you approach patients that develop atopic dermatitis while on biologics for psoriasis?

I have an elderly patient with a history of biopsy-proven psoriasis on IL-17 biologic therapy. She has developed an intense itch without a primary ras...

What lifestyle modifications do you recommend for patients with hidradenitis suppurativa?

What treatment modalities have you had success with for treating extensive molluscum in the pediatric population?

What lab monitoring and frequency do you recommend in an otherwise healthy young patient on biologics for psoriasis?

With no high-risk exposure do you repeat quant gold?

How do you approach treating disseminated granuloma annulare?

Do you order blood work to evaluate for underlying dyslipidemia or other metabolic diseases?

How do you manage axillary hyperhidrosis that is refractory to oral glycopyrrolate and aluminum-based antiperspirants in patients with neuromuscular disorders?

How do you manage atopic dermatitis in pediatric patients who has failed dupilumab?

(preschool-aged patients)

How do you approach HS patients with persistent HS lesions on the trunk?

Have you had success with deroofing or surgical excision? Is ILK the best option?

What is your treatment algorithm for managing porokeratosis?

How would you work up a patient with cutaneous mastocytosis?

Is a BM biopsy a must when there is skin involvement? If tryptase level is mildly elevated but less than 20 would you recommend a BM biopsy?

Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?

What approaches can we take to initiate therapy and improve survival rates in patients with HLH?

What nutritional supplements do you recommend for patients with hair loss?

Have you recommended supplementing less common supplements such as zinc or selenium?

What exfoliative regimen do you recommend for patients with recurrent plantar keratoderma?

What scented alternatives do you recommend patients with fragrance allergies try to replace perfumes/colognes?

Do your recommendations differ depending on the fragrance category (i.e fragrance mix I, II or balsam of Peru)?

What biologics have you found to be most effective in treating hidradenitis suppurativa?

How do you navigate insurance coverage?

Do you recommend testing for HPV in patients with oral lichen planus?

What skin care regimen do you prefer during radiation for patients with inflammatory breast cancer?

Are there any skin care products you would avoid in this population?

Do you avoid the use of hydroxychloroquine in patients with psoriasis and/or psoriatic arthritis?

Do you have concerns with the use of oral contraceptives in patients on JAK inhibitors given the black box warning for thromboembolic events?

How has this impacted your counseling and management?

Any concern for lupus flare in patients undergoing laser hair removal?

Do you transition to a topical retinoid after a patient completes a course of isotretinoin?

And if so how soon after do you start?

What recommendations do you make for patients with lower abdomen eczema from nickel in their belt buckle?

What is your preferred workup for a patient who has a biopsy consistent with “dermal hypersensitivity reaction”?

What treatment modalities have you tried for "dermal hypersensitivity reaction"?

What is your approach to patients with SLE who develop a rash after hydroxychloroquine initiation?

What is your approach for disease activity monitoring in patients with sarcoidosis?

What’s your approach to recurrent “idiopathic” Erythema Nodosum that failed NSAIDs?

What’s your preferred NSAIDs and next steps?

What is your treatment approach to prevent progression of phymatous rosacea?

Is isotretinoin the only effective option?

Do you have to remove gold dental crowns if patch testing reveals a gold allergy?

Do you prescribe fluocinolone in peanut oil in patients with peanut allergies?

What is your approach to treating genital lichen sclerosus that is not responding to super-potent topical steroids?

Is there a role for monitoring serum ANCAs to assess ANCA associated vasculitis disease activity?

This question is part of a collaboration with RheumMadness and is in reference to Pathogenic ANCA (RAVE Trial).

How do you perform patch testing in patients who are allergic to adhesives?

Does IVIG or subcutaneous Ig interfere with monoclonal antibody therapy (i.e. dupilumab, infliximab, rituximab, etc)?

How should IVIG and either biologic injections or infusions be spaced?

Do patient co-morbidities impact when you prescribe oral jak inhibitors?

Are you less likely to prescribe it for patients with dyslipidemia or autoimmune disease?

How do you manage recurrent urticarial lesions in a patient with underlying connective tissue disease that is otherwise well-controlled?

Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?

How do you approach treating patients with delusions of parasitosis who can not tolerate an antipsychotic?

What therapies have you found most effective for treating lower extremity DSAP?

Have you had success with topical lovastatin or PDT?

What is your approach to severe discoid lupus refractory to conventional topical and systemic therapies?

(Refractory to mycophenolate, azathioprine, and methotrexate. UpToDate suggests thalidomide or IVIG with mixed efficacy, while there are some case rep...

Do you have a preference between Quantiferon Gold and T-spot TB for screening in patients starting immunosuppressive agents?

What is your approach to evaluation in patients who present with erythromelalgia?

Does Dupixent interfere with patch testing?

Have you seen drug induced SCLE from IL-17 inhibitors?

And if so, what is your approach to the diagnosis?

What treatments do you recommend and how do you counsel patients with postpartum hair loss?

Do you recommend any dietary changes or supplements? Do you modify your recommendations if the patient is breast feeding?

How will you utilize newly FDA approved anifrolumab for SLE in your practice?

What initial workup do you perform when there is a concern for porphyria?

How do you counsel patients who report a history of a lidocaine allergy?

What treatments and resources have you found helpful for ichthyosis vulgaris patients?

What therapies have you found most helpful for recalcitrant non-infectious cases of folliculitis?

What treatments would you recommend for patients with chronic urticaria who have minimal improvement with anticholinergics and Xolair?

Have you tried any of the newer biologics?

How do you manage pityriasis lichenoides chronica (PLC)?

Do you typically order a systemic workup? And, after topical corticosteroids, what other treatment options do you prefer?

How do you monitor patients with cutaneous lupus for progression to SLE?

Do you do blood work? Or do you rely on review of systems?

How do you counsel parents of children with atopic dermatitis about preventing recurrent Staph infections?

Are dilute bleach baths enough? Should they use any topical therapies? Is there a need for Staph decolonization with something like mupirocin?

How do you approach treating patients with lupus profundus?

Do you typically start the patient on hydroxychloroquine? What work-up do you perform?

How do you manage injection site reactions in patients on subcutaneous biologics such as TNF inhibitors?

In what cases do you discontinue the medication?

How do you approach the diagnosis of erythronychia?

Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?

What is your approach to the use of intravenous sodium thiosulfate for the management of calciphylaxis in a patient with end stage kidney disease and on hemodialysis?

Do you use apremilast in combination with biologic DMARDs for psoriatic arthritis and/or psoriasis?

Are there ways to overcome barriers in insurance coverage of this combination of treatments?

At what age do you recommend annual skin exams in a patient without a personal or family history of skin cancer?

Any evidence behind this practice?

What prescription or over-the-counter therapies have you found effective for helping vitiligo patients cover active areas?

How do you approach treating nail lichen planus?

What topical therapies do you most commonly prescribe for rashes near the eyes?

What is your treatment algorithm for patients with lichen planus?

Do you measure drug levels (particularly hydroxychloroquine or mycophenolate) in your lupus patients?

Several speakers at ACR 2021 commented on the important role of drug levels in the management of these patients and cautioned against adding medicatio...

How would you approach treating patients with biopsy-proven Hailey- Hailey disease refractory to multiple oral therapies (i.e tetracyclines, naltrexone, apremilast, glycopyrrolate, Cellcept), and requiring monthly steroid tapers for disease flares?

The disease is responsive to ablative lasers however laser treatments are not an option.

Do all patients initiating omalizumab need to have it administered in a healthcare setting?

What therapies have you found most effective in providing rapid improvement in patients with erythrodermic atopic dermatitis?

What treatments have you found helpful in treating recurrent aphthous ulcers?

What lab monitoring do you perform for patients taking isotretinoin?

What labs do you order? How often do you order labs? Have you ever needed to discontinue isotretinoin due to lab abnormalities?

How do you manage patients with hand dermatitis recalcitrant to potent topical steroids?

When do you refer pediatric patients with eczema to an allergist?

Are there cases where food or environmental allergies significantly worsen eczema in children?

What is your treatment approach to persistent chillblains lesions in the absence of systemic lupus?

What treatments have you found to be most effective in treating oral lichen planus?

Does your treatment management differs for oral erosive lichen planus? How would you approach patients with active malignancy on chemo and radiation?

Do you routinely check G6PD level prior to initiation of hydroxychloroquine?

Have you had success using resorcinol 15% topically for limited hidradenitis?

If so, where can patients find it? And besides topical clindamycin, what other topicals do you find helpful for individual lesions?

How do you manage polymorphous eruption of pregnancy (formerly PUPPP)?

The symptoms can be really miserable.I try to control it with antihistamines (don't find these helpful in most cases) and topical steroids, but that d...

Would you consider using a JAK inhibitor in combination with an IL 23 inhibitor in cases of severe psoriasis, psoriatic arthritis, or axial spondyloarthritis that is refractory to multiple biologic DMARDs?

What topical therapies do you find are most effective for treating inverse psoriasis in areas of the body with thinner skin?

What methods do you use to prophylactically reduce radiation dermatitis for head and neck irradiation?

What recommendations do you provide to patients who develop ocular side effects with Dupixent?

Do you refer them to Ophthalmology? Have you had to switch patients off of Dupixent due to their ocular side effects?

Do you routinely provide GI protection in the form of a PPI or histamine blocker for patients with immunobullous disease initiated on high doses of oral corticosteroids?

How do you approach the management of patients on lamotrigine who develop a minor rash?

Should one restart lamotrigine or look for an alternative? If no other alternative available, is slow titration vs regular titration preferred?

How do you determine if a positive thimerosal patch test isn't a false positive?

Is a positive thimerosal test always a false positive?

Do you recheck screening labs (ESR, BUN/Cr, urinalysis, ANA, etc) for patients with recurrent small vessel vasculitis of unknown origin with each flare?

How do you manage patients on biologics peri-operatively?

Are there any medications that surgeons like discontinued before their procedure?

What is your approach to ongoing assessment and medication tapering in well controlled discoid lupus without systemic features?

What topical therapies and procedures do you recommend for patients with atrophic acne scarring?

What is your approach to using apremilast for psoriatic arthritis in patients with history of depression?

Do you hold histone deacetylase (HDAC) inhibitors for patients receiving palliative radiation therapy for cutaneous lymphomas?

If so, how long before/after radiation?

What topical or oral treatments do you recommend for patients with recurrent MRSA infections?

Do you recommend any changes to their personal hygiene practices? or changes to their environment?

What dressings do you recommend for patients with hidradenitis suppurativa to help prevent friction and collect drainage from open areas?

Especially after surgical procedures

What is your treatment approach for steroid-refractory necrobiosis lipoidica?

Any success with hydroxychloroquine?

How do you approach treating patients with erythema nodosum recalcitrant to NSAIDs?

What maintenance therapies do you most commonly recommend for patients with improving genital lichen sclerosis?

What recommendations do you provide if there is concern that the patient is beginning to flare? Have you prescribed any of the new JAK inhibitors?

How do you approach treating patients with trigeminal trophic syndrome?

How do you approach the treatment of bullous cutaneous lupus?

When would you de-escalate therapy?

How would you treat localized cutaneous PAN recalcitrant to high-dose steroids?

Where do oral and topical JAK inhibitors fit into your treatment algorithm and approach to atopic dermatitis?

What is your approach to a young adult patient with significant nail psoriasis and not much cutaneous disease?

What are some of your preferred treatment options for managing facial papules that occur in the setting of lichen planopilaris?

What is your approach to starting and monitoring methotrexate in elderly patients?

How do you evaluate livedo reticularis (not livideo racemosa)?

Does your evaluation hinge on nonresolution with warming? How extensive is your workup?

What is your work-up for acquired keratoderma?

Does morphology guide your workup?

When do you prescribe clascoterone cream for your acne patients?

In your experience, do specific patient features predict a better response?

What is your experience with iontophoresis for hyperhidrosis?

How do you approach treating necrobiosis lipoidica, especially cases that have ulcerated?

With the approval of oral JAK inhibitors such as Upadacitinib for atopic dermatitis, how are you considering its safety profile in comparison to traditional immunosuppressants such as prednisone, methotrexate, azathioprine, and mycophenolate?

Especially in the setting of these being more narrow acting than tofacitinib, should we consider them safer than our old drugs?

If you have clinical suspicion for a paraneoplastic process (e.g. dermatomyositis or pemphigus), what work-up do you pursue?

What treatment regimen do you start for patients who present with mucous membrane pemphigoid?

Have you prescribed Rituximab and IVIG simultaneously for patients?

How do you manage patients with erosive pustular dermatosis?

What are your preferred treatment options for patients with chronic non-healing leg ulcers?

What therapies do you recommend for preventing keloid recurrence after surgical resection?

How do you manage patients with Dercum's disease?

What is your approach to treating patients with dupilumab induced facial redness?

Do you recommend the HPV vaccine for patients with recalcitrant verruca vulgaris?

How do you manage patients with chronic flushing that do not respond to beta-blockers?

How do you manage patients with bullous pemphigoid who have IgE autoantibodies to BP180?

How do you manage patients with rapidly progressing vitiligo?

How do you manage patients with cicatricial pemphigoid refractory to doxycycline and dapsone?

How do you manage patients with chemotherapy-induced paronychia?

How do you approach treating cutaneous PAN?

Other than inflammatory markers and following symptoms/exam, do you need any other specific monitoring for progression to systemic disease?

How would you manage a patient with essential thrombocythemia and persistent pruritus despite adequate control of CBC with hydroxyurea and aspirin?

ET is JAK2+

How do you manage psoriasis in pregnant patients?

How do you approach restarting biologics for psoriasis patients who have discontinued therapy for 3-6 months?

Do you prefer restarting the biologic with the loading or maintenance dosing?

How do you approach patients with onychomycosis that does not respond to terbinafine and prolonged courses of fluconazole?

Would you switch to itraconazole or perform fungal cultures? When would you consider repeating the course of treatment?

How do you differentiate atopic dermatitis from mycosis fungoides histologically?

How do you manage patients with suspected chronic contact dermatitis and negative patch testing?

How long do you give systemic therapies or skin directed therapies to work before changing treatments in patients with diffuse skin limited mycoses fungoides?

Do you have a preferred sequence of therapies for diffuse skin limited MF?

Have you found success in managing refractory hidradenitis suppurativa with ertapenem?

Do you avoid dupilumab (IL-4 inhibition) for severe asthma in patients already taking a biologic agent for RA?

What is your preferred infliximab dosing strategy for hidradenitis suppurativa?

How do you approach the use of commercial testing such as AVISE CTD in clinical practice?

How do you clinically distinguish between cutaneous lupus with photosensitivity and polymorphic light eruption-like reactions?

What is the role for angiography in the workup of digital ischemia?

Do you obtain vascular imaging routinely in these cases, and if so, do you use cross-sectional or invasive angiography?

Is it ever reasonable to switch to a different TNFi as opposed to switching to an agent in a different class in a case of TNFi induced lupus or psoriasis?

In other words, do we think of TNFi induced lupus and TNFi induced psoriasis as a drug effect or a class effect?

What is your preferred regimen for remission induction and maintenance in EGPA with cardiac involvement?

How do you approach patients with ANCA vasculitis who had partial response, but continue to have disease activity on q 6 month maintenance rituximab and remain on steroids?

Would you change rituximab maintenance dose or schedule?

How do you choose between oral and IV cyclophosphamide for the treatment of ANCA-associated vasculitis?

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

ADVOCATE trial

When is it necessary to monitor the QTc interval in patients on hydroxychloroquine?

How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?

In the ADVOCATE trial, patients were not re-dosed with rituximab.

Are there particular subsets of AAV patients in which avacopan is more effective?

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

Is it okay to use medications associated with drug-induced lupus in patients with SLE?

How would you approach refractory gangrenous Raynaud's secondary to type one cryoglobulins?

What if the patient has MGUS? Do patients with type 1 cryoglobulins need a bone marrow biopsy as part of the work up?

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?

What treatment options are available for patients with spondyloarthritis who develop biologic-induced psoriasis?

Are there AAV patients for whom you would consider combination therapy with cyclophosphamide and rituximab?

Is there a role for measuring hydroxychloroquine blood levels in clinical practice?

If so, are there specific patient populations for which you would use this metric?

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

Are you recommending the mRNA COVID-19 vaccines to your patients with immune mediated inflammatory diseases?

Should venous thrombosis in a patient with Behcet syndrome be treated with both immunosuppression and anticoagulation?

How do you screen for colon cancer in patients with Behcet syndrome with colonic involvement?

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

Which immunosuppressed patients with SLE would benefit from antibiotic prophylaxis to prevent pneumocystis pneumonia?

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

Is it ever appropriate to use hydroxychloroquine temporarily in higher doses (more than 5mg/kg) to control lupus activity such as skin manifestations?

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

What agents can you use for treatment induction besides rituximab in cryoglobulinemic vasculitis (without hepatitis)?

Are there certain subsets of ANCA vasculitis patients for whom you would consider life long maintenance therapy?

How do you assess transaminitis in a patient with sarcoidosis with known liver involvement being treated with methotrexate?

Do you continue hydroxychloroquine in lupus patients who develop cardiomyopathy?

When is a biopsy necessary to diagnose relapsing polychondritis?

What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?

How do you manage calcium and vitamin D supplementation in patients with sarcoidosis on chronic steroids?

What clinical factors do you use to determine timing of on-demand dosing of rituximab in ANCA vasculitis maintenance therapy?

Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?

If you use both, how do you decide which to use for a particular patient?

Are there any clinical situations in which checking for anti-chromatin antibodies is helpful?

How do you counsel patients who ask if there are any dietary modifications they can make to help control their autoimmune disease?

This question is part of a collaboration with RheumMadness and is specifically in reference to: ADIRA Diet

Is there a minimum work-up necessary in patients with an ANA greater than 1:160 and no clinical symptoms suggestive of lupus (i.e., specific antibodies, UA)?

Do you use hydroxychloroquine for prevention of neonatal lupus in patients with a positive SSA who are planning on becoming pregnant?